Company Website:
http://ovascience.com
CAMBRIDGE, Mass. -- (Business Wire)
OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that additional clinical experience
of the Company’s AUGMENTSM treatment demonstrated improved
pregnancy rates in women who had failed three to seven prior in vitro
fertilization (IVF) cycles. These results were reported at the Society
for Reproductive Investigation (SRI) 62nd Annual Scientific
Meeting being held in San Francisco, CA. The AUGMENT treatment is not
available in the United States.
Kutluk Oktay, M.D., F.A.C.O.G, of Gen-art IVF in Ankara, Turkey, and one
of the initial IVF specialists to use the AUGMENT treatment in clinical
practice, presented initial clinical experience in eight women whose
ages ranged between 27 and 41 years with three or more IVF failures and
poor egg and embryo quality. In eight women who received the AUGMENT
treatment, there were two clinical pregnancies out of eight embryo
transfers (25%).1 Most notably, the two pregnancies occurred
with single embryo transfers in women aged 34 and 41 who had previously
failed to become pregnant following seven and three IVF cycles,
respectively. One patient has an ongoing clinical pregnancy.2
“These initial AUGMENT pregnancy rates are quite encouraging, especially
given that these were women who had failed multiple IVF cycles and were
running out of options to use their own eggs,” said Dr. Oktay. “We were
also pleased to see these pregnancy rates achieved with single embryo
transfers during IVF, a practice that may limit the number of multiple
births, which can cause health risks to the mother and infant during
pregnancy and delivery and after. Based on our experiences to date, the
AUGMENT treatment appears to benefit women with poor egg quality and we
look forward to continuing to share our clinical experiences.”
The results reported in the poster presentation represent experiences
from a small number of patients with different diagnoses, ages and prior
IVF history. As of this reporting, pregnancy rates across IVF clinics
that offer the AUGMENT treatment currently range from 25% - 53%, which
includes clinics that are treating some of the more challenging
infertility patients. OvaScience is collecting AUGMENT patient
experience in a first-of-its-kind international registry, and
anticipates sharing information from a broader patient experience when
it is available.
The AUGMENT treatment is a fertility treatment specifically designed to
use the mitochondria, or energy, from a woman’s own egg precursor cells
– immature egg cells found inside the protective ovarian lining – to
improve egg health. The treatment is available to patients in select
international IVF clinics. Additional information can be found at www.augmenttreatment.com.
“The positive clinical evidence continues to build in support of our
AUGMENT treatment,” stated Michelle Dipp, M.D., Ph.D., Chief Executive
Officer of OvaScience. “These improved pregnancy rates in women who have
failed IVF multiple times, coupled with similar encouraging clinical
AUGMENT experiences at other IVF clinics, provide physicians and
patients with important information about how the AUGMENT treatment may
improve egg health in women with infertility.”
Dr. Oktay’s poster presentation follows an AUGMENT presentation made by
Robert Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility
Partners, at the SRI meeting. Both presentations can be found at www.ovascience.com/technology/publications.
The AUGMENT treatment presentations at SRI are based on self-reported
patient experiences and physician evaluations.
About OvaScience
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to
improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because we believe women deserve more options. Each OvaScience treatment
is based on the Company’s proprietary technology platform that leverages
the breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions outside of the United States. OvaScience is
developing the OvaPrimeSM treatment, which could increase a
woman’s egg reserve, and the OvaTureSM treatment, a potential
next-generation IVF treatment that could help a woman produce healthy,
young, fertilizable eggs without hormone injections. For more
information, please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.
Forward-Looking Statements
This press release includes forward-looking statements about the
Company’s plans for the AUGMENT treatment and future pregnancy rates.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to: the possibility that international IVF
clinics that we work with may determine not to begin or continue
providing the AUGMENT treatment for commercial or other reasons; our
expectation that the AUGMENT treatment and OvaPrime treatment meet the
requirements of a class of products exempt from premarket review and
approval under applicable regulations in those countries where we have
launched or plan to introduce the AUGMENT treatment and plan to
introduce the OvaPrime treatment; the commercial ramp up of the AUGMENT
treatment, which we expect will depend upon the successful transition of
ACE clinics to commercial operations, the addition of new ACE clinics,
and the results from ACE clinic experience as they become available; the
science underlying our treatment and treatments in development
(including the AUGMENT, OvaPrime and OvaTure treatments), which is
unproven; our ability to obtain regulatory approval where necessary for
our potential treatments; our ability to develop our potential
treatments, including the OvaPrime and OvaTure treatments, on the
timelines we expect, if at all; our ability to commercialize the AUGMENT
treatment and our potential treatments, including the OvaPrime
treatment, on the timelines we expect, if at all; as well as those risks
more fully discussed in the “Risk Factors” section of our most recently
filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K.The forward-looking statements contained in this press release
reflect our current views with respect to future events.We
anticipate that subsequent events and developments will cause our views
to change. However, while we may elect to update these forward-looking
statements in the future, we specifically disclaim any obligation to do
so. These forward-looking statements should not be relied upon as
representing our view as of any date subsequent to the date hereof.
###
1 Outcomes presented show percentage of clinical pregnancies
from embryo transfer.
2 Clinical pregnancy is defined as a pregnancy diagnosed by
ultrasound. http://www.eshre.eu/Guidelines-and-Legal/ART-glossary.aspx
Contacts:
OvaScience
Theresa McNeely, 617-299-7356
EVP, Chief
Communications Officer
tmcneely@ovascience.com
or
Media
Cara
Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com
Source: OvaScience
© 2024 Canjex Publishing Ltd. All rights reserved.